Clinical significance of diffusely increased splenic uptake on FDG-PET

Nuclear Medicine Communications

Volumn 30, Issue 10, 2009, Pages 763-769

  Liu, Yiyan ^a  

^a University of Medicine and Dentistry of New Jersey   (United States)

Author keywords

FDG PET CT; HIV infection; Lymphoma; Sarcoidosis; Splenic uptake

Indexed keywords

ALPHA2B INTERFERON; CYTOKINE; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

B LYMPHOCYTE ACTIVATION; BLOOD DISEASE; BONE MARROW; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INFILTRATION; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC ERROR; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATORY DISEASE; INTERMETHOD COMPARISON; LYMPHOMA; MALARIA; MELANOMA; NK T CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SARCOIDOSIS; SPLEEN; SPLEEN CANCER; SPLEEN DISEASE; SPLEEN SCINTISCANNING; SPLENOMEGALY; WHOLE BODY CT; WHOLE BODY PET;

FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SPLEEN; SPLENIC DISEASES;

EID: 70349108435     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32832fa254     Document Type: Review

References (54)

1. Metser U, Miller E, Kessler A, Lerman H, Lievshitz G, Oren R, et al. Solid splenic mass: evaluation with 18F-FDG PET/CT. J Nucl Med 2005; 46 :52-59.
2. Brox A, Shustik C. Non-Hodgkin's lymphoma of the spleen. Leuk Lymphoma 1993; 11:165-171.
3. Kadin ME, Glaststein EJ, Dorfman RE. Clinicopathologic studies in 117 untreated patients subject to laparotomy for the staging of Hodgkin's disease. Cancer 1977; 27:1277-1294.
4. Kutok JL, Fletcher CD. Splenic vascular tumors. Semin Diagn Pathol 2003; 20 :128-139.
5. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2 deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189:847-850.
6. Kotzerke J, Guhlmann A, Moog F, Frickhofen N, Reske SN. Role of attenuation correction for fluorine-18-fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Eur J Nucl Med 1999; 26:31-38.
7. Meier JM, Alavi A, Iruvuri S, Alzeair S, Parker R, Houseni M, et al. Assessment of age-related changes in abdominal organ structure and function with computed tomography and positron emission tomography. Semin Nucl Med 2007; 37:154-172. (Pubitemid 46517469)
8. Rini J, Manalili EY, Hoffman MA, Karayalcin G, Mehrotra B, Tomas M, et al. F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease. Clin Nucl Med 2002; 27:572-577.
9. Bangerter M, Moog F, Buchmann I, Kotzerke J, Griesshammer M, Hafner M, et al. Whole body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography for accurate staging of Hodgkin's disease. Ann Oncol 1998; 9 :1117-1122.
10. Urba WJ, Longo DL. Hodhkin's disease. N Engl J Med 1992; 326:678-683.
11. Silechia G, Fantini A, Raparelli L. Management of abdominal lymphoproliferative disease in the era of laparoscopy. Am J Surg 1999; 177:325-329.
12. Fishman EK, Kuhlman JE, Jones RJ. CT of lymphoma: spectrum of disease. RadioGraphics 1991; 11:647-669.
13. Castellino RA. Hodgkin's disease: practical concepts for the diagnostic radiologists. Radiology 1986; 159:305-310.
14. Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000; 11:1273-1279.
15. Munker R, Stengel A, Stabler A, Hiller E, Brehm G. Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin's disease. Cancer 1995; 76:1460-1466.
16. Rini JN, Leonidas JC, Tomas MB, Palestro CJ. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med 2003; 44 :1072-1074.
17. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190:111-116.
18. Moog F, Bangerter M, Diederichs CG, Guhlman A, Merkle E, Frickhofen N. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998; 206:474-481.
19. Friedberg JW, Fishman A, Neuberg D, Kim H, Takvorian T, NG AK, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 2004; 45:85-92.
20. Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, et al. The usefulness of 18F FDG-PET and a comparison of 18F FDG-PET with gallium scintigraphy in the evaluation of lymphoma: relation of histologic subtypes based on the World Health Organization classification. Cancer 2007; 110:652-659.
21. Rutherford S, Andemariam B, Philips S, Elstrom R, Chadburn A, Furman RR, et al. FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. Leuk Lymphoma 2008; 49:719-726.
22. Ford CD, Gabor F, Morgan R, Dabbas B. False positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma. Clin Nucl Med 2006; 31:391-393.
23. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007; 25 :571-578.
24. Hicks RJ, Manus MP, Seymour JF. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 2005; 35 :165-175.
25. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma - comparison with CT. Leuk Lymphoma 2000; 39:543-553.
26. Basu S, Chryssikos T, Moghadam-Kia S, Zhuang H, Torigian DA, Alavi A. Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med 2009; 39:36-51.
27. Scharko AM, Perlman SB, Hinds PW, Hanson JM, Uno H, Pauza CD. Whole body positron emission tomography imaging of simian immunodeficiency virus-infected rhesus macaques. Proc Natl Acad Sci USA 1996; 93:6425-6430.
28. Scharko AM, Perlman SB, Pyzalski RW, Graziano FM, Sosman J, Pauza CD. Whole body positron emission tomography in patients with HIV-1 infection. Lancet 2003; 362:945-950.
29. Iyengar S, Chin B, Margolick JB, Sabundayo BP, Schwartz DH. Anatomical foci of HIV-associated immune activation and association with viraemia. Lancet 2003; 362:945-950.
30. Brust D, Polis M, Davey R, Hahn B, Bacharach S, Whatley M, Fauci A, et al. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS 2006; 20 :985-993.
31. Tan KK, Chen K, Sim R. The spectrum of abdominal tuberculosis in a developed country: a single institution's experience over 7 years. J Gastrointest Surg 2009; 13:142-147.
32. Gore RM, Miller FH, Yaghmai V. Acquired immunodeficiency syndrome (AIDS) of the abdominal organs: imaging features. Semin Ultrasound CT MR 1998; 19:175-189.
33. Warshauer DM. Splenic sarcoidosis. Semin Ultrasound CT MR 2007; 28 :21-27.
34. Ebert EC, Kierson M, Hagspiel KD. Gastrointestinal and hepatic manifestations of sarcoidosis. Am J Gastrointesterol 2008; 103:3184-3192.
35. Penna C, Deroide GA. Images in clinical medicine. Splenic sarcoidosis. N Engl J Med 2003; 349:e16.
36. Folz SJ, Johnson CD, Swensen SJ. Abdominal manifestations of sarcoidosis in CT studies. J Comput Assist Tomogr 1995; 19:573-579.
37. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35:1647-1649.
38. Chundru S, wong CY, Wu D, Balon H, Plaka J, Chang CY, et al. Granulomatous disease: is it a nuisance or an asset during PET/computed tomography evaluation of lung cancers. Nucl Med Commun 2008; 29 :623-627.
39. Kaira K, Oriuchi N, Otani Y, Yanagitani N, Sunaga N, Hisada T, et al. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest 2007; 131:1019-1027.
40. Kawai S, Ikeda E, Sugiyama M, Matsumoto J, Higuchi T, Zhang H, et al. Enhancement of splenic glucose metabolism during acute malarial infection: correlation of findings of FDG-PET imaging with pathological changes in a primate model of severe human malaria. Am J Trop Med Hyg 2006; 74 :353-360.
41. Engwerda CR, Beattie L, Amnte FH. The importance of the spleen in malaria. Trends Parasitol 2005; 21:75-80.
42. Naheel A, Yun M, Alavi A. F-18 FDG uptake in congestive splenomegaly. Clin Nucl Med 2002; 27:210.
43. Tomas MB, Tronco GG, Karayalcin G, Palestro CJ. FDG uptake in infectious mononucleosis. Clin Positron Imaging 2000; 3:176.
44. Lustberg MB, Aras O, Meisenberg BR. FDG PET/CT findings in acute adult mononucleosis mimicking malignant lymphoma. Eur J Haematol 2008; 81 :154-156.
45. Sheehy N, Israel DA. Acute varicella infection mimics recurrent Hodgkin's disease on F-18 FDG PET/CT. Clin Nucl Med 2007; 32:820-821.
46. Burrell SC, Fischman AJ. Myelofibrosis on F-18 FDG PET imaging. Clin Nucl Med 2005; 30:674.
47. Wong CL, Fulham MJ. Increased splenic FDG uptake on PET in beta-thalassemia. Clin Nucl Med 2004; 29:266-267.
48. Sugawara Y, Zasadny K, Kison PV, Baker LH, Wahl RL. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results. J Nucl Med 1999; 40 :1456-1462.
49. Kazama T, Swanston N, Podoloff DA, Macapinlac HA. Effect of colony-stimulating factor and conventional- or high dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging 2005; 32 :1406-1411.
50. Jacene HA, Ishimori T, Engles JM, Leboulleux S, Stearns V, Wahl RL. Effect of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. J Nucl Med 2006; 47:950-956.
51. Litam PP, Friedman HD, Loughran TP Jr. Splenic extramedullary hematopoiesis in a patient receiving intermittently administered granulocyte colony-stimulating factor. Ann Intern Med 1993; 118:954-955.
52. Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006; 106:1431-1442.
53. Cone LA, Brochert A, Schulz K, Stone RA, Kazi A, Greene D. PET positive generalized lymphadenopathy and splenomegaly following interferon-alfa-2b adjuvant therapy for melanoma. Clin Nucl Med 2007; 32:793-796.
54. Ridolfi L, Cangini D, Galassi R, Passardi A, Marzullo A, Moretti A, et al. Reversible, PET-positive, generalized lymphadenopathy and splenomegaly during high dose interferon-alfa-2b adjuvant therapy for melanoma. J Immunother 2008; 31:675-678.